Lonza further strengthens US manufacturing presence with addition of a commercial spray-drying facility in Bend, Oregon
Lonza is adding spray-drying manufacturing capacity in the US, increasing supply of processed pharmaceutical materials.
Source →The trace
How it reaches your house.
Starting from Lonza Group, we walked the supply graph hop by hop to the goods you buy and the companies you own. Each step is the engine’s reasoning, scored for confidence and cited where a source backs it.
First impact
Lonza Group AG (Pharmaceutical Chemicals / PAA) →supply upprocessed pharmaceutical materials
The source explicitly says Lonza will build a new large-scale spray-drying facility to support a rapidly expanding market segment, which implies more output of processed pharmaceutical materials.
“Lonza will build a new large-scale, commercial PSD-4 spray-drying facility in Bend, Oregon (US) to support a rapidly expanding market segment”
94% confidenceCited →Lonza Group →supply upGLP-1 Receptor Agonist Peptide API (Semaglutide / Liraglutide Type)
Lonza’s new commercial spray-drying capacity should raise availability of its processed pharmaceutical output, and this GLP-1 peptide API line is the closest matching supplied input in the graph.
52% confidenceHop 2
Where it lands
What you buy, and what you own.
Goods you buy
GLP-1 drugs (Ozempic, Wegovy, Mounjaro)
Companies you may own
No named companies on this path.
Tap a company to see what it told the SEC could break it.
In the MyPRIA app, this is checked against your own holdings.